Delivery outcome after the use of meclozine in early pregnancy

European Journal of Epidemiology

Volumn 18, Issue 7, 2003, Pages 665-670

  Källén, Bengt ^a   Mottet, Isabelle ^b  

^a UNIVERSITY OF LUND   (Sweden)

^b Tornblad Institute ^*

Author keywords

Congenital malformations; Meclozine; Nausea and vomiting in pregnancy; Preterm birth

Indexed keywords

ANTICONVULSIVE AGENT; ANTIHYPERTENSIVE AGENT; MECLOZINE; THYROXINE;

ADULT; ARTICLE; BODY HEIGHT; BODY MASS; CONGENITAL MALFORMATION; CONTROLLED STUDY; DELIVERY; DRUG SAFETY; FEMALE; HEAD CIRCUMFERENCE; HUMAN; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MANTEL HAENSZEL TEST; MATERNAL AGE; MATERNAL DIABETES MELLITUS; NAUSEA AND VOMITING; NAUSEA AND VOMITING IN PREGNANCY; NEWBORN; PARITY; PREECLAMPSIA; PREGNANCY; PREMATURE LABOR; PROSPECTIVE STUDY; RISK FACTOR; SEX RATIO; SMOKING; SWEDEN; TWIN PREGNANCY;

EID: 0041520831     PISSN: 03932990     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024891618953     Document Type: Article

References (16)

1. King CT. Teratogenic effect of meclizine hydrochloride on the rat. Science 1983; 141: 353-355.
2. Giurges M, Pudgdevall J. Experimental teratology with meclozine. Med Exp 1966; 15: 375-388.
3. Nelson MM, Forfar JO. Association between drug administration during pregnancy and congenital abnormalities of the fetus. Br Med J 1971; i: 523-527.
4. Greenberg G, Inman WhW, Weatherall JAC, Adelskin AM, Haskey JC. Maternal drug history and congenital abnormalities. Br Med J 1977; ii: 853-856.
5. Shapiro S, Kaufman DW, Rosenberg L, et al. Meclizine in pregnancy in relation to congenital malformations. Br Med J 1978; i: 483.
6. Milkovich L, van der Berg BJ. An evaluation of the teratogenicity of certain antinauseant drug. Am J Obst Gynecol 1983; 125: 244-248.
7. Cnattingius S, Ericson A, Gunnarskog J, Källén B. A quality study of a medical birth registry. Scand J Soc Med 1990; 18: 143-148.
8. Källén B. Search for teratogenic risks with the aid of malformation registries. Teratology 1987; 35: 47-52.
9. Källén B. A birth weight for gestational age standard based on data in the Swedish Medical Birh Registry, 1985-1989. Eur J Epidemiol 1995; 11: 601-606.
10. Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. Am J Obst Gynecol 1965; 93: 553-562.
11. Kullander S, Källén B. A prospective study of drugs and pregnancy. II. Antiemetic drugs. Acta Obst Gynecol Scand 1976; 55: 105-111.
12. Lacroix R, Eason E, Melzack R. Nausea and vomiting during pregnancy: A prospective study of its frequency, intensity, and patterns of change. Am J Obst Gynecol 2000; 182: 931-937.
13. Clausson B, Granath F, Ekbom A, et al. Effect of caffeine exposure during pregnancy on birth weight and gestational age. Am J Epidemiol 2002; 158: 429-436.
14. Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: Meta-analysis. Am J Perinatol 1994; 14: 119-124.
15. Magee LA, Mazzotta P, Koren G. Evidence-based view of safety and effectiveness of pharmacologic therapy for nausea and vomiting of pregnancy (NVP). Am J Obst Gynecol 2002; 186 (Suppl 2): 256-261.
16. Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Maternal-Fetal Neonatal Med 2002; 11: 146-152.